Anti-Diabetes Drugs - Lithuania | Statista Market Forecast

In Lithuania, the revenue in the Anti-Diabetes Drugs market is estimated to reach US$24.11m by 2024.
It is anticipated that there will be an annual growth rate (CAGR 2024-2029) of 7.44%, leading to a market volume of US$34.52m by 2029.
When compared globally, United States is projected to generate the most revenue, with an estimated US$37.84bn in 2024.
In Lithuania, there is a growing demand for innovative and affordable anti-diabetes drugs to combat the rising prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Lithuania has been experiencing steady growth in recent years.

Customer preferences: The Lithuanian population has been increasingly concerned with their health and well-being, leading to a higher demand for diabetes medications. Patients are also becoming more aware of the importance of early diagnosis and treatment, which has led to an increase in the number of people seeking medical attention for diabetes.

Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Lithuania is the shift towards more innovative and effective treatments. Patients are demanding medications that are not only effective in managing their diabetes but also have fewer side effects. This has led to an increase in the use of newer drugs such as DPP-4 inhibitors and GLP-1 receptor agonists.Another trend that has been observed in the market is the increasing use of combination therapies. Patients are no longer relying on a single medication to manage their diabetes, but are instead using a combination of drugs to achieve better blood sugar control. This has led to an increase in the sales of combination drugs such as metformin and sulfonylurea.

Local special circumstances: One of the unique aspects of the Anti-Diabetes Drugs market in Lithuania is the high prevalence of type 2 diabetes among the elderly population. This has led to an increased demand for medications that are specifically designed for older patients, such as those that are less likely to cause hypoglycemia.Another local circumstance that has had an impact on the market is the relatively low level of public awareness about diabetes. This has led to a delay in the diagnosis and treatment of the disease, which has in turn led to a higher demand for medications that are effective in managing the condition.

Underlying macroeconomic factors: One of the key macroeconomic factors driving the growth of the Anti-Diabetes Drugs market in Lithuania is the country's aging population. As the population continues to age, the prevalence of diabetes is expected to increase, which will drive demand for diabetes medications.Another factor that is driving the growth of the market is the increasing availability of healthcare services in the country. As more people have access to healthcare, the number of people seeking treatment for diabetes is expected to increase, which will drive demand for diabetes medications.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.